Drug Profile
AGS 004
Alternative Names: AGS-004; AGS-004-001; ArcelisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Argos Therapeutics Inc; Kirin Holdings Company
- Developer Argos Therapeutics Inc
- Class Antivirals; Dendritic cell vaccines; Viral vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 11 Jul 2018 University of North Carolina and National Institute of Allergy and Infectious Diseases terminates the pilot phase I VORVAX trial for HIV-1 infections in USA (PO) (NCT02707900)
- 16 Feb 2018 Argon Therapeutics receives patent allowance for manufacturing HIV immunotherapy in US
- 26 Jul 2017 Immunogenicity and adverse events data from a phase I/II trial in HIV-1 infections released by Argos Therapeutics